ArticleJournal of medical physics
Single-institution Experience for Interrupted Radiotherapy in Magnetic Resonance Guided Accelerator.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In July 2024, a major failure in our magnetic resonance-guided linear accelerator (MR-linac) led to a 2-week treatment interruption for four patients. Objective: To evaluate the clinical outcomes and toxicities at the end of the treatment, and up to 6 months after dose compensation for treatment interruption. Materials and Methods: Following the guidelines of the Royal College of Radiologists, we hypo fractionated the treatments. The dose per fraction and number of fractions were recalculated using the linear-quadratic model. Results: Despite the treatment delay, the adapted dose had minimal impact on the oncological outcomes in the follow-up up to 6 months posttreatment. All patients demonstrated adequate tolerance to toxicity with no disease progression. Two patients achieved complete responses, while two showed partial responses. Conclusion: Hypofractionation proved to be a feasible strategy for managing treatment interruptions in MR-linac adaptive radiotherapy, ensuring treatment continuity without compromising safety and efficacy. The biological approach maintained tumor control while minimizing toxicity, demonstrating its potential for broader applications in similar clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.